Clinical insights into paraneoplastic cerebellar degeneration.
Neuroimaging is usually unremarkable in paraneoplastic cerebellar degeneration (PCD), at least in the early stages of the disease. A patient with proven PCD is reported in whom it could be shown that cerebellar atrophy evolved very rapidly and was present in early imaging studies. Even with the use of the whole spectrum of modern diagnostic tools, the underlying malignancy can be difficult to diagnose. In addition to mammography, MRI is recommended in these cases and repeat FDG-PET may be necessary.
Scheid
R
R
Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. scheid@cbs.mpg.de
Voltz
R
R
Briest
S
S
Kluge
R
R
von Cramon
D Y
DY
D000328:Adult; D001259:Ataxia / Q000175:diagnosis; D001284:Atrophy / Q000473:pathology; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery; D044584:Carcinoma, Ductal / Q000473:pathology / Q000601:surgery; D002528:Cerebellar Neoplasms / Q000175:diagnosis / Q000473:pathology*; D002531:Cerebellum / Q000473:pathology; D003937:Diagnosis, Differential; D018450:Disease Progression; D004401:Dysarthria / Q000175:diagnosis; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D008881:Migraine Disorders / Q000175:diagnosis; D010048:Ovarian Cysts / Q000000981:diagnostic imaging; D020362:Paraneoplastic Cerebellar Degeneration / Q000175:diagnosis / Q000473:pathology*; D049268:Positron-Emission Tomography; D011689:Purkinje Cells / Q000473:pathology; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18